Author pages are created from data sourced from our academic publisher partnerships and public sources.
The Potential for Misuse and Abuse of Medications in ADHD: A Review
Abstract This article reviews the literature concerning attention-deficit/hyperactivity disorder (ADHD) medication misuse, abuse, dependence, diversion, and malingering. The review covers nonmedical… Expand
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
- S. Andersen, D. Clemow, S. Corya
- Psychology, Medicine
- The Journal of clinical psychiatry
- 15 November 2005
OBJECTIVE Patients with major depressive disorder (MDD) treated with olanzapine in combination with fluoxetine (OFC) demonstrate robust improvement in their depressive symptoms. Treatment with… Expand
Atomoxetine Effects on Executive Function as Measured by the BRIEF-A in Young Adults with ADHD: A Randomized, Double-Blind, Placebo-Controlled Study
Objective To evaluate the effect of atomoxetine treatment on executive functions in young adults with attention-deficit/hyperactivity disorder (ADHD). Methods In this Phase 4, multi-center,… Expand
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder
Abstract Background: Attention-deficit/hyperactivity disorder (ADHD) is a CNS disorder that has its onset in childhood, but often persists into adulthood. There is growing recognition that adult ADHD… Expand
Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc…
- R. Tanenberg, D. Clemow, J. M. Giaconia, R. Risser
- Pain practice : the official journal of World…
- 1 September 2014
To examine the efficacy of duloxetine vs. pregabalin in the treatment for diabetic peripheral neuropathic pain (DPNP), comparing patient subgroups with and without concomitant antidepressant use.
Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients
This article reviews data providing new insight into the trajectory of response and maintenance of response of atomoxetine in the treatment of child and adult attention-deficit hyperactivity disorder… Expand
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
- D. Clemow, C. Bushe, M. Mancini, M. Ossipov, H. Upadhyaya
- Neuropsychiatric disease and treatment
- 3 February 2017
Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that is often diagnosed during childhood, but has also increasingly been recognized to occur in adults.… Expand
Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
- K. Mcburnett, D. Clemow, D. Williams, Miguel T Villodas, L. Wietecha, R. Barkley
- Journal of child and adolescent…
OBJECTIVES To evaluate effects of atomoxetine versus placebo on sluggish cognitive tempo (SCT) and determine factors affecting improvement of SCT in children with attention-deficit/hyperactivity… Expand
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study
- D. Clemow, Oren W. Mason, +8 authors A. Araújo
- Expert review of neurotherapeutics
- 21 October 2015
Objective: To analyze Clinical Global Impression—Severity (CGI-S) in ADHD patients treated with atomoxetine (ATX) monotherapy versus ATX combination therapy with another ADHD-indicated medication.… Expand
Misuse of Methylphenidate.
- D. Clemow
- Current topics in behavioral neurosciences
- 23 December 2015
This chapter reviews methylphenidate misuse, abuse, dependence, diversion, and malingering associated with its use as a prescription medication for attention-deficit/hyperactivity disorder and the… Expand